Scenarios that move DXCM
DexCom, Inc. - Common Stock
Scenarios that move DXCM: 8 analyses, 2 positive, 6 negative.
- · Viking Therapeutics advances oral obesity drug to Phase III — ▼ · impact -8 · confidence low · horizon quarters
- · Zealand Pharma reports positive survodutide Phase III weight loss results — ▼ · impact -18 · confidence low · horizon quarters
- · Novo Nordisk's Ozempic outperforms Lilly's Mounjaro on cardiovascular risk — ▲ · impact +25 · confidence low · horizon quarters
- · Lilly reports strong weight loss results for new drug — ▼ · impact -22 · confidence low · horizon quarters
- · Novo and Hengrui sign exclusive license for oral GLP-1/GIP drug — ▼ · impact -15 · confidence low · horizon quarters
- · Beta Bionics stock plunges 37% after safety issues emerge — ▼ · impact -14 · confidence low · horizon quarters
- · Viking Therapeutics stock skyrockets in Tuesday trading — ▼ · impact -13 · confidence low · horizon quarters
- · Beta Bionics prices public offering of stock and warrants — ▲ · impact +37 · confidence medium · horizon quarters